Reiko Matsuzawa1, Masahiro Morise2, Fumie Kinoshita3, Ichidai Tanaka1, Junji Koyama1, Tomoki Kimura4, Yasuhiro Kondoh4, Taro Tanaka5, Koichiro Shima5, Tetsunari Hase1, Keiko Wakahara1, Makoto Ishii1, Naozumi Hashimoto1. 1. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 tsurumai, Showa-ku, Nagoya, 466-8560, Japan. 2. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 tsurumai, Showa-ku, Nagoya, 466-8560, Japan. morisem@med.nagoya-u.ac.jp. 3. Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan. 4. Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan. 5. Department of Respiratory Medicine, Ekisaikai Hospital, Nagoya, Japan.
Abstract
PURPOSE: We determined the clinical relevance of early C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) change in blood as surrogate markers of pro-tumor inflammation (PTI) for predicting clinical outcome of programmed cell death (PD)-1/programmed cell death ligand (PD-L) 1 inhibitor treatment in non-small-cell lung carcinoma (NSCLC). METHODS: We retrospectively reviewed NSCLC patients treated with anti-PD-1 or PD-L1 inhibitors. Early CRP change was defined as the ratio of 6 weeks CRP to baseline CRP, and early NLR change was defined as that of the 6 weeks NLR to baseline NLR. PTI index was determined by combinatorial evaluation of early CRP change and early NLR change, PTI index low: both of these were low, intermediate: either of these was low, high; both of these were high. RESULTS: The study included 217 patients. Early CRP change and early NLR change were both associated with PFS and OS. The combinatorial evaluation using these two markers enabled the clear stratification of PFS and OS. The median PFS in patient with PTI index low was 13.9 months, while the median PFS in those with PTI index high was 2.5 months (p < 0.01, log-rank test). The median OS in patients with PTI index low was not reached; the median OS in those with PTI index high was only 15.4 months (p < 0.01, log-rank test). CONCLUSIONS: The combinatorial early CRP change and early NLR change as PTI biomarkers have clinical potential in identifying NSCLC patients who can achieve a durable response and long-term survival using PD-1/PD-L1 inhibitors.
PURPOSE: We determined the clinical relevance of early C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) change in blood as surrogate markers of pro-tumor inflammation (PTI) for predicting clinical outcome of programmed cell death (PD)-1/programmed cell death ligand (PD-L) 1 inhibitor treatment in non-small-cell lung carcinoma (NSCLC). METHODS: We retrospectively reviewed NSCLC patients treated with anti-PD-1 or PD-L1 inhibitors. Early CRP change was defined as the ratio of 6 weeks CRP to baseline CRP, and early NLR change was defined as that of the 6 weeks NLR to baseline NLR. PTI index was determined by combinatorial evaluation of early CRP change and early NLR change, PTI index low: both of these were low, intermediate: either of these was low, high; both of these were high. RESULTS: The study included 217 patients. Early CRP change and early NLR change were both associated with PFS and OS. The combinatorial evaluation using these two markers enabled the clear stratification of PFS and OS. The median PFS in patient with PTI index low was 13.9 months, while the median PFS in those with PTI index high was 2.5 months (p < 0.01, log-rank test). The median OS in patients with PTI index low was not reached; the median OS in those with PTI index high was only 15.4 months (p < 0.01, log-rank test). CONCLUSIONS: The combinatorial early CRP change and early NLR change as PTI biomarkers have clinical potential in identifying NSCLC patients who can achieve a durable response and long-term survival using PD-1/PD-L1 inhibitors.
Authors: Rina Hui; Mustafa Özgüroğlu; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Takashi Yokoi; Alberto Chiappori; Ki Hyeong Lee; Maike de Wit; Byoung Chul Cho; Jhanelle E Gray; Anna Rydén; Louis Viviers; Lynne Poole; Yiduo Zhang; Phillip A Dennis; Scott J Antonia Journal: Lancet Oncol Date: 2019-10-07 Impact factor: 41.316
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Tatsuya Yoshida; Junya Ichikawa; Iulia Giuroiu; Andressa S Laino; Yuhan Hao; Michelle Krogsgaard; Melinda Vassallo; David M Woods; F Stephen Hodi; Jeffrey Weber Journal: J Immunother Cancer Date: 2020-04 Impact factor: 13.751
Authors: Alissa Keegan; Biagio Ricciuti; Padric Garden; Limor Cohen; Reiko Nishihara; Anika Adeni; Cloud Paweletz; Julianna Supplee; Pasi A Jänne; Mariano Severgnini; Mark M Awad; David R Walt Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751